Milestone adds two directors, plans third under agreement with Alta activist investor

Milestone Pharmaceuticals Inc.

Appointed Stuart Duty and Andrew Saik as independent directors effective July 14, 2024.
Cooperation agreement: Alta withdraws director nominations; Milestone to appoint third mutually agreeable independent by Sept 6, 2024.
Directors Debra Liebert and Richard Pasternak will not stand for reelection (no disagreement).
Alta agrees to standstill and vote with board recommendations until after 2025 annual meeting.
Board size to rise to nine then reduce to eight after 2024 meeting and third appointment.

item 1.01 item 5.02 item 5.08 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.